Page 3 - Nasdaq Immx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Immx Today - Breaking & Trending Today

Immix Biopharma Announces Additional NXC-201 AL Amyloidosis

LOS ANGELES, Aug. 16, 2023 (GLOBE NEWSWIRE) Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company. ....

Polina Stepensky , Mike Moyer , International Myeloma Working Group , Immix Biopharma Inc , View Research , International Myeloma Society Annual Meeting , Exchange Commission , Nexcella Inc , Hadassah Medical Organization , Bone Marrow Transplantation , Presentation Details , Multiple Myeloma , Uniform Response Criteria , Grand View , Immix Biopharma , Tissue Specific Therapeutic , Orphan Drug Designation , Rare Pediatric Disease Designation , Risk Factor , Annual Report , Nasdaq Immx , Immix Biopharma , Xc 201 Al Amyloidosis ,

Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Increases By 8.2%

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 59,300 shares, an increase of 8.2% from the July 15th total of 54,800 shares. Based on an average daily volume of 240,700 shares, the days-to-cover ratio is currently 0.2 […] ....

United States , Roth Mkm , Renaissance Technologies , Topco Ltd , Virtu Financial , Vanguard Group Inc , Immix Biopharma Inc , Immix Biopharma , Get Free Report , Biopharma Trading Down , Street Corp , Vanguard Group , Immix Biopharma Daily , Nasdaq Immx ,

Immix Biopharma Subsidiary Nexcella Announces NXC-201

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023. ....

United States , Alex Lobo , Los Angeles , Polina Stepensky , Immix Biopharma Inc , Nexcella Inc , International Myeloma Society Annual Meeting , Immix Biopharma Inc Nasdaq , International Myeloma Working Group , Exchange Commission , Immix Biopharma , Hadassah Medical Organization , Bone Marrow Transplantation , Multiple Myeloma , Uniform Response Criteria , Tissue Specific Therapeutics , Orphan Drug Designation , Rare Pediatric Disease Designation , Risk Factor , Annual Report , Nasdaq Immx , Immix Biopharma ,

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.1%

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was down 6.1% during trading on Monday . The stock traded as low as $2.03 and last traded at $2.15. Approximately 478,451 shares changed hands during mid-day trading, an increase of 90% from the average daily volume of 252,189 shares. The stock had previously closed at $2.29. […] ....

United States , Immix Biopharma Inc , Topco Ltd , Virtu Financial , Lynwood Capital Management Inc , Susquehanna International Group , Immix Biopharma , Get Free Report , Montreal Can , International Group , Lynwood Capital Management , Immix Biopharma Daily , Nasdaq Immx ,

Immix Biopharma Subsidiary Nexcella Completes Pre-IND

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a. ....

Ilya Rachman , Gabriel Morris , Alex Lobo , Los Angeles , Immix Biopharma Inc , Nexcella Inc , International Myeloma Working Group , Exchange Commission , Immix Biopharma , Pre Investigational New Drug , Chief Executive Officer , Chief Financial Officer , Multiple Myeloma , Uniform Response Criteria , Tissue Specific Therapeutics , Orphan Drug Designation , Rare Pediatric Disease Designation , Risk Factor , Annual Report , Nasdaq Immx , Immix Biopharma , Nxc 201 ,